Souhaitez-vous accéder aux communiqués récents ?

GHENT, Belgium, July 1, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication...

Exclusive license agreement with Taisho Pharmaceutical Co, Ltd., to develop and commercialise ozoralizumab in Japan for the treatment of rheumatoid arthritis (RA) Ablynx to receive an upfront...

GHENT, Belgium, June 17, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that additional data from the post-hoc analysis of the worldwide Phase II TITAN study...

REGULATED INFORMATION GHENT, Belgium, June 5, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and...

GHENT, Belgium, May 28, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces it will present at the Annual Jefferies 2015 Global Healthcare Conference in New York City...

REGULATED INFORMATION GHENT, Belgium, May 26, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...

REGULATED INFORMATION GHENT, Belgium, May 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...

GHENT, Belgium, May 18, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into an exclusive research collaboration with Genzyme, a Sanofi...

REGULATED INFORMATION Total revenue and grant income up 26% to €14.1 million Key clinical programmes moving forward More than 20 collaborative programmes advancing with all six...

GHENT, Belgium, May 7, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] presented an overview of its unique and versatile Nanobody platform and its application for inhaled...